Astellas Announces Status of Acquisition of Own Shares

TOKYO, March 1, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “the Company”) announced the status of acquisition of its own shares as stated below. The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

Particulars

1. Class of shares acquired:　　　　 　  Common stock of the Company
    
2. Total number of shares acquired:　　15,153,600 shares
    
3. Total amount of acquisition cost:　　 29,023,551,450 yen
    
4. Period of acquisition:　　　　　　　  From February 7, 2023 to February 28, 2023
    
5. Method of acquisition:　　　　　 　   Market purchase on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on February 6, 2023)
   (1) Class of shares to be acquired:　　　　   Common stock of the Company
   (2) Total number of shares to be acquired:　Up to 29 million shares
        (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.59%)
   (3) Total amount of acquisition cost:　　　   Up to 50 billion yen
   (4) Period of acquisition:　　　　　　　　     From February 7, 2023 to March 24, 2023
   (5) Method of acquisition:　　　　　　　　   Market purchase on the Tokyo Stock Exchange
    
2. Accumulated Company’s own shares acquired through February 28, 2023, pursuant to the above board resolution
   (1) Total number of shares acquired:　　　  15,153,600 shares
   (2) Total amount of acquisition cost:　　　   29,023,551,450 yen

Click below for a copy of the full press release